Literature DB >> 29343527

Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.

Kevin Falzon1,2, Evangelos Drimtzias1, Susan Picton1, Ian Simmons1.   

Abstract

AIMS: To report visual acuity (VA) outcomes following chemotherapy for optic pathway glioma (OPG) in children with or without neurofibromatosis type-1 (NF1) and to analyse associated risk factors.
METHODS: A prospective, multicentre, cohort study involving 155 children treated between September 2004 and December 2012. Initial and final VA was used for per-eye and per-subject analysis. Correlation tests were performed to determine whether initial VA predicted final VA. Logistic regression was used to determine whether age and tumour location were associated risk factors.
RESULTS: 90 children had complete ophthalmological data. At initiation of chemotherapy, 26% and 49% of eyes with NF1-OPG and sporadic OPG, respectively, had VA of ≥0.7 log of the minimum angle of resolution (logMAR). At final visit, per eye, 49% had ≤0.2, 23% had 0.30-0.60 and 28% had VA≥0.70 logMAR in the NF1-OPG group. In the sporadic OPG group, per eye, 32% had ≤0.2, 11% had VA 0.30-0.60 and 57% had ≥0.70 logMAR. Children with sporadic OPG, per eye, were significantly less likely to have VA outcomes ≤0.60 logMAR compared with children with NF1-OPG (OR=0.30; 95% CI 0.16 to 0.56; P<0.0001). Per subject, VA improved in 24%, remained stable in 35% and worsened in 41% of children with NF1-OPG and improved in 18%, remained stable in 43% and worsened in 39% of children with sporadic OPG.
CONCLUSIONS: Children with and without NF1 demonstrated the same rate of VA improvement, stabilisation or worsening; however, children with sporadic OPG had a poorer VA outcome. Better initial VA, older age, absence of postchiasm tumour and presence of NF1 were associated with improved or stable VA outcomes. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  child health (paediatrics); optic nerve; visual pathway

Mesh:

Substances:

Year:  2018        PMID: 29343527     DOI: 10.1136/bjophthalmol-2017-311305

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma.

Authors:  Sahaja Acharya; Sophia Quesada; Kenneth Coca; Cody Richardson; Mary E Hoehn; Jason Chiang; Ibrahim Qaddoumi; Frederick A Boop; Amar Gajjar; Thomas E Merchant
Journal:  J Neurooncol       Date:  2019-08-14       Impact factor: 4.130

2.  Optic Nerve Gliomas.

Authors:  Edward J Wladis; Matthew A Adamo; Lauren Weintraub
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

3.  Visual outcomes and predictors in optic pathway glioma: a single centre study.

Authors:  R Bowman; B Walters; V Smith; K L Prise; S E Handley; K Green; K Mankad; P O'Hare; C Dahl; M Jorgensen; E Opocher; D Hargrave; D A Thompson
Journal:  Eye (Lond)       Date:  2022-05-13       Impact factor: 3.775

4.  Ophthalmological Findings in Youths With a Newly Diagnosed Brain Tumor.

Authors:  Myrthe A Nuijts; Inge Stegeman; Tom van Seeters; Marloes D Borst; Carlien A M Bennebroek; Dennis R Buis; Nicole C Naus; Giorgio L Porro; Michelle B van Egmond-Ebbeling; Elisabeth S M Voskuil-Kerkhof; JanWillem R Pott; Niels E Franke; Evelien de Vos-Kerkhof; Eelco W Hoving; Antoinette Y N Schouten-van Meeteren; Saskia M Imhof
Journal:  JAMA Ophthalmol       Date:  2022-10-01       Impact factor: 8.253

5.  Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience.

Authors:  Giada Del Baldo; Antonella Cacchione; Vito Andrea Dell'Anna; Pietro Merli; Giovanna Stefania Colafati; Antonio Marrazzo; Sabrina Rossi; Isabella Giovannoni; Sabina Barresi; Annalisa Deodati; Paola Valente; Elisabetta Ferretti; Mara Capece; Angela Mastronuzzi; Andrea Carai
Journal:  Front Surg       Date:  2022-06-16

6.  Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.

Authors:  Chelsea Kotch; Robert Avery; Kelly D Getz; Eric Bouffet; Peter de Blank; Robert Listernick; David H Gutmann; Miriam Bornhorst; Cynthia Campen; Grant T Liu; Richard Aplenc; Yimei Li; Michael J Fisher
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

Review 7.  Visual function tests including the role of optical coherence tomography in neurofibromatosis 1.

Authors:  Daphna Mezad-Koursh; Anat Bachar Zipori; Dinah Zur; Lior Degabli; Meital Ben-Dov; Ainat Klein
Journal:  Childs Nerv Syst       Date:  2020-08-04       Impact factor: 1.475

8.  A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Authors:  Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Olivia Campagne; Anu Banerjee; Sridharan Gururangan; Lindsay B Kilburn; Stewart Goldman; Ibrahim Qaddoumi; Patricia Baxter; Gilbert Vezina; Corey Bregman; Zoltan Patay; Jeremy Y Jones; Clinton F Stewart; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300

Review 9.  Neurosurgical experience of managing optic pathway gliomas.

Authors:  Ciaran Scott Hill; Mehdi Khan; Kim Phipps; Katherine Green; Darren Hargrave; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2021-02-03       Impact factor: 1.475

10.  NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.

Authors:  María Jesús Lobón-Iglesias; Ingrid Laurendeau; Léa Guerrini-Rousseau; Arnault Tauziède-Espariat; Audrey Briand-Suleau; Pascale Varlet; Dominique Vidaud; Michel Vidaud; Laurence Brugieres; Jacques Grill; Eric Pasmant
Journal:  Neurooncol Adv       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.